Investing in Better Therapeutics Inc (BTTX): What You Must Know

Better Therapeutics Inc’s filing revealed that its Executive Chairman PERRY DAVID P acquired Company’s shares for reported $0.9 million on Jul 27. In the deal valued at $0.73 per share,1,233,045 shares were bought. As a result of this transaction, PERRY DAVID P now holds 13,030,393 shares worth roughly $2.61 million.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Then, Parker Geoffrey M. bought 685,025 shares, generating $500,000 in total proceeds. Upon buying the shares at $0.73, the Director now owns 1,028,055 shares.

Before that, Armanino Andrew J. bought 274,010 shares. Better Therapeutics Inc shares valued at $200,000 were divested by the Director at a price of $0.73 per share. As a result of the transaction, Armanino Andrew J. now holds 728,368 shares, worth roughly $0.15 million.

Chardan Capital Markets initiated its Better Therapeutics Inc [BTTX] rating to a Buy in a research note published On Monday, November 24, 2021; the price target was $17.

Price Performance Review of BTTX

On Monday, Better Therapeutics Inc [NASDAQ:BTTX] saw its stock jump 6.17% to $0.20. Over the last five days, the stock has lost -1.00%. Better Therapeutics Inc shares have risen nearly 1.54% since the year began. Nevertheless, the stocks have fallen -86.15% over the past one year. While a 52-week high of $1.61 was reached on 01/11/24, a 52-week low of $0.14 was recorded on 01/04/24. SMA at 50 days reached $0.2033, while 200 days put it at $0.5619. A total of 1.14 million shares were traded, compared to the trading of 1.59 million shares in the previous session.

Levels Of Support And Resistance For BTTX Stock

The 24-hour chart illustrates a support level at 0.1860, which if violated will result in even more drops to 0.1740. On the upside, there is a resistance level at 0.2050. A further resistance level may holdings at 0.2120. The Relative Strength Index (RSI) on the 14-day chart is 48.42, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0218, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 77.20%. Stochastics %K at 20.87% indicates the stock is a holding.

How much short interest is there in Better Therapeutics Inc?

A steep rise in short interest was recorded in Better Therapeutics Inc stocks on Jan 11, 2024, dropping by -0.47 million shares to a total of 1.37 million shares. Yahoo Finance data shows the prior-month short interest on Dec 14, 2023 was 1.84 million shares. There was a decline of -34.31%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 4.64% of the overall stock float, the days-to-cover ratio (short ratio) fell to 0.52.

Better Therapeutics Inc [BTTX] – Who Are The Largest Shareholders?

In filings from MM Asset Management, Inc., it is revealed that the company now owns 1,583,079 shares, or roughly 3.18% of the outstanding BTTX shares. Additionally, The Vanguard Group, Inc. increased 14.01% of its stake after which the total value it holdings stand at $97,480, while Geode Capital Management LLC reduced -12.20% of its stake to hold $20841.0 in the firm. Over the last quarter, BlackRock Fund Advisors sold -1,365 shares of Better Therapeutics Inc, while SSgA Funds Management, Inc. sold 13,400 shares. At present, Capital Investment Advisory Servi is holding 41,000 shares valued at $7995.0. Millennium Management LLC owned 36,873 shares of the company at the time of its most recent 13F filing, worth $7190.0.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular